Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Gliatech

This article was originally published in The Gray Sheet

Executive Summary

Gliatech: Nets $19.8 mil. from initial public offering of 2.3 mil. shares at $9.50 a share. The issue will be traded on the NASDAQ exchange under the symbol "GLIA," the firm states. Cleveland-based Gliatech announced plans for the IPO during the summer ("The Gray Sheet" Sept. 11, p. 13). Net proceeds will go toward manufacturing and marketing in Europe of the Cleveland-based firm's Adcon line of products to control surgical adhesion, clinical trials of the products in the U.S. and Europe, working capital and general corporate purposes. The offering was managed by Montgomery Securities, Vector Securities International, and McDonald & Company Securities...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel